5-乙基-4-甲基-2-(1-甲基乙基)-噻唑 | 53498-31-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-乙基-4-甲基-2-(1-甲基乙基)-噻唑
• 英文名称: Thiazole, 5-ethyl-4-methyl-2-(1-methylethyl)-
• 英文别名: 5-ethyl-4-methyl-2-propan-2-yl-1,3-thiazole
• CAS: 53498-31-0
• 化学式: C₉H₁₅NS
• 分子量: 169.29
• InChiKey: AYEGWZGUAQDVNB-UHFFFAOYSA-N

物化性质

• 沸点：
  225.3±9.0 °C(Predicted)
• 密度：
  0.988±0.06 g/cm3(Predicted)
• LogP：
  2.224 (est)
• 保留指数：
  1179;1179;1179;1179

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  41.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE
  申请人：Kameda Minoru

  公开号：US20120028970A1

  公开（公告）日：2012-02-02

  The present invention relates to a compound represented by a formula (I): wherein X is a group represented by or the like; Y is a group represented by or the like; and Ar 1 is a group represented by or a pharmaceutically acceptable salt thereof.

  本发明涉及一种由式(I)表示的化合物：其中X是由等表示的基团；Y是由等表示的基团；Ar1是由等表示的基团或其药学上可接受的盐。
• INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：Chen Wei

  公开号：US20160031891A1

  公开（公告）日：2016-02-04

  Disclosed herein are amido compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文公开了一种与布鲁顿酪氨酸激酶（Btk）形成共价键的酰胺化合物。还描述了Btk的不可逆抑制剂。还公开了包括这些化合物的药物组合物。公开了使用Btk抑制剂的方法，单独或与其他治疗剂一起用于治疗自身免疫性疾病或病况，异体免疫性疾病或病况，癌症，包括淋巴瘤和炎症性疾病或病况。
• ERK INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20170266167A1

  公开（公告）日：2017-09-21

  The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.
• US9533991B2
  申请人：——

  公开号：US9533991B2

  公开（公告）日：2017-01-03